Morbidity, mortality, and management of methicillin-resistant S. aureus bacteremia in the USA: update on antibacterial choices and understanding

Jessica K. Ortwine, Kavita Bhavan

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is associated with significant healthcare costs, morbidity, and mortality in the United States. Complications of MRSA bacteremia include infective endocarditis, osteomyelitis, and sepsis, all of which are difficult to treat. Time to effective therapy and antibacterial choice greatly affect patient outcomes. Vancomycin and daptomycin remain first-line therapies; however, reports of vancomycin-associated treatment failure and reduced daptomycin susceptibility highlight the need to define alternative strategies for MRSA bacteremia treatment. In addition, several patient- and pathogen-specific factors influence the outcomes of MRSA bacteremia. It is, therefore, critical to explore the interaction between host- and pathogen-specific factors and its effect on MRSA bacteremia pathogenesis and mortality. This review discusses the factors that drive the development of MRSA bacteremia and examines alternative treatment strategies.

Original languageEnglish (US)
Pages (from-to)64-72
Number of pages9
JournalHospital practice (1995)
Volume46
Issue number2
DOIs
StatePublished - Apr 1 2018

Keywords

  • Bacteremia
  • ceftaroline
  • dalbavancin
  • daptomycin
  • linezolid
  • methicillin-resistant S. aureus
  • oritavancin
  • Staphylococcus aureus
  • telavancin
  • vancomycin

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Morbidity, mortality, and management of methicillin-resistant S. aureus bacteremia in the USA: update on antibacterial choices and understanding'. Together they form a unique fingerprint.

Cite this